MILESTONE PHARMACEUTICALS IN (MIST) Fundamental Analysis & Valuation

NASDAQ:MIST • CA59935V1076

Current stock price

1.38 USD
+0.07 (+5.34%)
At close:
1.4601 USD
+0.08 (+5.8%)
After Hours:

This MIST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MIST Profitability Analysis

1.1 Basic Checks

  • In the past year MIST has reported negative net income.
  • In the past year MIST has reported a negative cash flow from operations.
  • In the past 5 years MIST always reported negative net income.
  • MIST had a negative operating cash flow in each of the past 5 years.
MIST Yearly Net Income VS EBIT VS OCF VS FCFMIST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -55.53%, MIST is doing worse than 65.63% of the companies in the same industry.
  • The Return On Equity of MIST (-150.97%) is worse than 69.79% of its industry peers.
Industry RankSector Rank
ROA -55.53%
ROE -150.97%
ROIC N/A
ROA(3y)-63.29%
ROA(5y)-60.8%
ROE(3y)-274.22%
ROE(5y)-189.76%
ROIC(3y)N/A
ROIC(5y)N/A
MIST Yearly ROA, ROE, ROICMIST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MIST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIST Yearly Profit, Operating, Gross MarginsMIST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MIST Health Analysis

2.1 Basic Checks

  • MIST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MIST has more shares outstanding than it did 1 year ago.
  • MIST has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MIST has an improved debt to assets ratio.
MIST Yearly Shares OutstandingMIST Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MIST Yearly Total Debt VS Total AssetsMIST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • MIST has an Altman-Z score of -4.40. This is a bad value and indicates that MIST is not financially healthy and even has some risk of bankruptcy.
  • MIST has a Altman-Z score of -4.40. This is in the lower half of the industry: MIST underperforms 61.46% of its industry peers.
  • MIST has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
  • MIST has a Debt to Equity ratio of 1.37. This is in the lower half of the industry: MIST underperforms 76.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Altman-Z -4.4
ROIC/WACCN/A
WACC8.2%
MIST Yearly LT Debt VS Equity VS FCFMIST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 8.01 indicates that MIST has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.01, MIST is in the better half of the industry, outperforming 77.60% of the companies in the same industry.
  • A Quick Ratio of 7.96 indicates that MIST has no problem at all paying its short term obligations.
  • MIST has a Quick ratio of 7.96. This is in the better half of the industry: MIST outperforms 77.60% of its industry peers.
Industry RankSector Rank
Current Ratio 8.01
Quick Ratio 7.96
MIST Yearly Current Assets VS Current LiabilitesMIST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MIST Growth Analysis

3.1 Past

  • MIST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.56%.
  • MIST shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -32.38% yearly.
EPS 1Y (TTM)-17.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.55%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.38%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 27.81% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.27%
EPS Next 2Y-0.84%
EPS Next 3Y8.1%
EPS Next 5Y27.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIST Yearly Revenue VS EstimatesMIST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MIST Yearly EPS VS EstimatesMIST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. MIST Valuation Analysis

4.1 Price/Earnings Ratio

  • MIST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MIST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIST Price Earnings VS Forward Price EarningsMIST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIST Per share dataMIST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.84%
EPS Next 3Y8.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MIST Dividend Analysis

5.1 Amount

  • No dividends for MIST!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MIST Fundamentals: All Metrics, Ratios and Statistics

MILESTONE PHARMACEUTICALS IN

NASDAQ:MIST (4/2/2026, 8:00:01 PM)

After market: 1.4601 +0.08 (+5.8%)

1.38

+0.07 (+5.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-20
Earnings (Next)05-12
Inst Owners40.78%
Inst Owner Change-21.39%
Ins Owners3.97%
Ins Owner Change-0.05%
Market Cap117.53M
Revenue(TTM)1.55M
Net Income(TTM)-63.06M
Analysts80
Price Target6.73 (387.68%)
Short Float %10.71%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.98%
Min EPS beat(2)-10.29%
Max EPS beat(2)28.26%
EPS beat(4)1
Avg EPS beat(4)-14.19%
Min EPS beat(4)-64.28%
Max EPS beat(4)28.26%
EPS beat(8)4
Avg EPS beat(8)-2.52%
EPS beat(12)7
Avg EPS beat(12)0.78%
EPS beat(16)10
Avg EPS beat(16)2.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-55.2%
EPS NQ rev (3m)-55.2%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)220.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 76.02
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB 2.81
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.02
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.53%
ROE -150.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.29%
ROA(5y)-60.8%
ROE(3y)-274.22%
ROE(5y)-189.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 264.91%
Cap/Sales 19.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.01
Quick Ratio 7.96
Altman-Z -4.4
F-Score4
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)139.36%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.55%
EPS Next Y35.27%
EPS Next 2Y-0.84%
EPS Next 3Y8.1%
EPS Next 5Y27.81%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.38%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.87%
EBIT Next 3Y21.32%
EBIT Next 5Y35.57%
FCF growth 1Y-70.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70%
OCF growth 3YN/A
OCF growth 5YN/A

MILESTONE PHARMACEUTICALS IN / MIST Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MILESTONE PHARMACEUTICALS IN (MIST) stock?

ChartMill assigns a fundamental rating of 1 / 10 to MIST.


What is the valuation status of MILESTONE PHARMACEUTICALS IN (MIST) stock?

ChartMill assigns a valuation rating of 0 / 10 to MILESTONE PHARMACEUTICALS IN (MIST). This can be considered as Overvalued.


How profitable is MILESTONE PHARMACEUTICALS IN (MIST) stock?

MILESTONE PHARMACEUTICALS IN (MIST) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MIST stock?

The Earnings per Share (EPS) of MILESTONE PHARMACEUTICALS IN (MIST) is expected to grow by 35.27% in the next year.